You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Development of Manufacturing Technology for the Practical Application of Specialized and Environmentally Sensitive Nutrients, Enzymes, Immune-Stimulating Compounds and Biologics to Aquafeeds
SBC: Zeigler Bros, Inc. Topic: 823FIn an effort to support the development of a domestic marine aquaculture industry, Zeigler Bros. Inc., (ZBI) proposes to continue its Phase I research by demonstrating the ability to scale up inclusion particle (IP) manufacturing. During Phase II ZBI will also demonstrate the efficacy of IOs for orally delivering phytase and probiotics to marine finfish. These efforts will directly address the p ...
SBIR Phase II 2013 Department of CommerceNational Oceanic and Atmospheric Administration -
Advanced In-Shoe Orthotic Treatment for Foot Pain
SBC: DIAPEDIA, LLC Topic: NIADESCRIPTION (provided by applicant): This Phase II SBIR proposal describes a strategy and work plan for accelerating to market a new device that will provide an evidence-based, patient-specific solution to a significant public health problem: foot pain. The TrueContour(R) therapeutic insole system was originally conceived for prevention of forefoot injury in diabetes mellitus. We propose to furth ...
SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health -
Actuated Low-Force Biopsy Tool for Versatile Bone Lesion Access with Less Trauma
SBC: ACTUATED MEDICAL, INC. Topic: NCIDESCRIPTION (provided by applicant): In this Phase II SBIR, Actuated Medical, Inc. will complete the development of the Actuated Low-Force Biopsy Tool for Versatile Bone Lesion Access with Less Trauma. Public Health Problem: Percutaneous bone biopsy is performed to obtain tissue for specific diagnosis of bone lesions identified through imaging or clinical evaluation. A major disadvantage of the ...
SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health -
Riluzole Prodrugs for Melanoma and ALS
SBC: FOX CHASE CHEMICAL DIVERSITY CENTER INC. Topic: NCIDESCRIPTION (provided by applicant): We have identified a novel Type IIb prodrug of riluzole, FC-311, which has the potential to revolutionize therapy for the treatment of the devastating condition of metastatic melanoma acting via a novel glutamatergic mechanism of action, and also be useful to treat amyotrophic lateral sclerosis (ALS) and the many other conditions for which riluzole itself is un ...
SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health -
Surgical Adhesive for Seroma Prevention
SBC: COHERA MEDICAL, INC. Topic: NIGMSDESCRIPTION (provided by applicant): Seroma formation (fluid accumulation in the wound) is among the most common post-surgical complications, occurring in up to 50% of certain surgical procedures. TissuGlu(R) Surgical Adhesive is designed to adhere flaps of tissue and prevent the accumulation of fluid in surgical wounds, thereby reducing the need for drains and improving the time to recovery. Trad ...
SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health -
Continuous Real Time CSF Shunt Flow Monitor ShuntCheck
SBC: NEURODX DEVELOPMENT LLC Topic: NINDSDESCRIPTION (provided by applicant): This Phase II SBIR will develop Continuous Real Time (CRT) ShuntCheck, the first portable, non- invasive device for real time, continuous monitoring of changes in flow in CSF shunts. This device will result in improvedclinical management of hydrocephalus by providing a non-invasive method for monitoring and researching shunt function. Hydrocephalus, a common co ...
SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health -
Preserving beta-lactam utility vs pathogens producing any class of beta-lactamase
SBC: VENATORX PHARMACEUTICALS INC Topic: NIAIDDESCRIPTION provided by applicant Multi drug resistance in Enterobacteriaceae is regarded as a healthcare crisis This crisis has been further amplified by the recent emergence of the NDM andquot super bug geneandquot a zinc based metallo lactamase Amber Class B in Enterobacteriaceae Members of this family of resistance enzymes are found on promiscuous plasmids with other MDR resistance mechanisms ...
SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health -
Phase II SBIR: Responding to NDM-1- Advancement of a new MBL inhibitor to IND
SBC: VENATORX PHARMACEUTICALS INC Topic: NIAIDDESCRIPTION provided by applicant Multi drug resistance in Enterobacteriaceae is regarded as a healthcare crisis While carbapenems are among the most prescribed antibiotics for infections caused by these organisms carbapenem resistance conferred by zinc based metallo carbapenemases Amber Class B is a growing global health concern that threatens to erode the efficacy of these antibiotics both in th ...
SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health -
In-Patient Pediatric Gastrojejunal Tube Cleaner Eliminating Surgical Intervention
SBC: ACTUATED MEDICAL, INC. Topic: NICHDDESCRIPTION provided by applicant In this Phase II NIH SBIR Actuated Medical Inc will complete the development of the Pedi GJ ClearTM device for clearing occlusions and restoring patency in situ to pediatric gastrojejunal feeding tubes GJ tubes eliminating the need to surgically replace clogged tubes Public Health Problem Enteral nutrition is provided for patients that have a functioning lower gas ...
SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health -
Development of a Urine Test for the Early Detection of Liver Cancer
SBC: JBS SCIENCE INC Topic: NCIDESCRIPTION provided by applicant Development of a urine test for the early detection of liver cancer The need to develop an effective method of detecting hepatocellular carcinoma HCC is urgent HCC is the third leading cause of cancer deaths and has a year survival rate of less than If HCC is identified early the survival rate can be as high as The survival rate drops significantly however to as l ...
SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health